[144] BeOne Medicines Ltd. American SEC Filing

Rhea-AI Filing Summary

BeOne Medicines Ltd. (ONC) filing a Form 144 reports a proposed sale of 2,665 common shares with an aggregate market value of $898,105.00. The securities were acquired and are planned to be sold on 09/05/2025 following an exercise of options under a registered plan, with cash payment recorded on that date. The broker listed for the proposed sale is Morgan Stanley Smith Barney LLC, Executive Financial Services, New York and the sale is expected to occur on NASDAQ. The filer states there were no securities sold in the past three months by the selling person and includes the standard representation that the seller does not possess undisclosed material adverse information about the issuer.

Insights

Financial Analyst

TL;DR: Insider-derived shares (via option exercise) totaling 2,665 shares are being offered for sale the same day, showing a routine post-exercise disposition.

The filing documents a proposed sale of 2,665 common shares acquired and to be sold on 09/05/2025 after exercising options under a registered plan. The aggregate market value reported is $898,105.00 and the broker is Morgan Stanley Smith Barney LLC. There are no reported sales in the prior three months. This appears procedural: an option exercise followed by a contemporaneous sale through a major broker on NASDAQ. Material impact to company capitalization or control is unlikely given the small share count relative to the reported 54,564,278 shares outstanding, but investors may note insider liquidity events as routine issuer-related transactions.

Corporate Governance Expert

TL;DR: The Form 144 is a standard disclosure of a post-exercise sale; it includes the required representations and no unusual conditions are disclosed.

The notice includes the seller’s attestation that no undisclosed material adverse information exists and references the standard legal warning about misstatements. The transaction is described as an exercise under a registered plan with cash payment and scheduled sale on the same date. From a governance and disclosure perspective, the filing meets Rule 144 disclosure elements: acquisition details, broker identity, planned sale date, and prior three-month sales. There is no indication of a Rule 10b5-1 plan adoption date in the remarks, so no automated trading-plan protection is asserted in this notice.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	2665	898105.00	54564278	09/05/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/05/2025	Exercise of options under a registered plan	Issuer			2665	09/05/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What securities did ONC disclose for proposed sale in this Form 144?

The filer proposes to sell 2,665 common shares of BeOne Medicines Ltd. (ONC) with an aggregate market value of $898,105.00.

When were the shares acquired and when is the proposed sale date?

The shares were acquired by exercise of options under a registered plan on 09/05/2025 and the approximate date of sale is listed as 09/05/2025.

Through which broker will the ONC shares be sold and on what exchange?

The broker is listed as Morgan Stanley Smith Barney LLC, Executive Financial Services and the sale is expected on NASDAQ.

Were any ONC securities sold by the same person in the past three months?

The filing states "Nothing to Report" for securities sold during the past three months by the person for whose account the securities are to be sold.

Does the filer assert possession of undisclosed material information about ONC?

By signing the notice, the person represents they do not know any material adverse information regarding the issuer that has not been publicly disclosed.